Pfizer Continues Positive Data Readouts For JAK Inhibitor Abrocitinib In Eczema

 
• By Joseph Haas
  
woman in a laboratory microscope with microscope slide in hand.toned image.
Pfizer continues to build a case for its JAK1 inhibitor in atopic dermatitis

More from Clinical Trials

More from R&D